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Abstract
Purpose The purpose of the current study is to determine
the in vitro cytotoxic eVects of the novel pan-PI3-kinase
inhibitor SF1126 in HER2-over-expressing breast cancer
cells.
Methods Cell proliferation and cytotoxicity were exam-
ined by MTS colorimetric assay, FACS analysis, colony
formation assay, and immunoblotting. Phosphoinositol-3-
kinase signaling was assessed by immunoblotting for phos-
phorylated Akt. Combination eVects of trastuzumab and
SF1126 were examined in resistant cells by MTS and soft
agar assay.
Results SF1126 inhibited proliferation, and induced G1
arrest and apoptosis of SKBR3 and BT474 parental and
trastuzumab-resistant HER2-over-expressing cells. Colony
formation was inhibited by SF1126, caspase 3 and PARP
proteins were cleaved, and survivin was down-regulated.
Inhibition of PI3-kinase was conWrmed by reduced phos-
phorylation of Akt. Finally, the combination of SF1126 and
trastuzumab synergistically inhibited proliferation of resis-
tant cells, with SF1126-treated cells showing reduced
anchorage-independent growth.
Conclusions These results provide evidence that a clini-
cally relevant pan-PI-3 kinase inhibitor can reverse trast-
uzumab resistance in breast cancer cells, and support
further study of PI3-kinase inhibitor SF1126 in HER2-
over-expressing breast cancer cells, including those that
have progressed on trastuzumab.
Keywords Targeted therapy · Herceptin · 
Drug resistance · PI3-kinase
Introduction
The human epidermal growth factor receptor 2 (her2) gene
is ampliWed and/or over-expressed in approximately 20–
30% of invasive breast carcinomas, and is associated with
increased metastatic potential and decreased overall patient
survival [1]. Trastuzumab (Herceptin; Genentech, South
San Francisco, CA) is a recombinant humanized monoclo-
nal antibody directed against an extracellular domain of the
HER2 tyrosine kinase receptor [2]. Clinical studies established
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that trastuzumab is active against HER2-over-expressing
metastatic breast cancers [3–5], leading to its approval in
1998 by the US Food and Drug Administration. However,
the objective response rates to trastuzumab monotherapy
were low, ranging from 12 to 34% for a median duration of
9 months [4, 5]. Even in combination with chemotherapy,
response duration to trastuzumab is less than 1 year [6].
Thus, considerable eVort has been made over the past
decade to understand the mechanisms leading to trast-
uzumab resistance and to identify novel agents for patients
with HER2-over-expressing metastatic breast cancer.
The anti-neoplastic eVects of trastuzumab appear to
require binding of the therapeutic antibody to HER2 with
subsequent inhibition of downstream signaling through the
phosphoinositol-3-kinase (PI3K)/Akt pathway. Constitutive
Akt activity has been shown to block trastuzumab-mediated
growth arrest and apoptosis in HER2-over-expressing
breast cancer cells [7]. In addition, increased PI3K/Akt sig-
naling due to downregulation of the phosphatase and tensin
homolog (PTEN) or due to oncogenic mutations in the
catalytic subunit of the PI3 kinase has been associated
with reduced response to trastuzumab in patients with
HER2-over-expressing breast cancer [8, 9]. Based on these
Wndings, there is clear rationale for testing PI3K inhibitors
in trastuzumab-resistant breast cancers.
Previous pre-clinical studies have suggested that Akt
inhibition is a potentially eVective strategy for HER2-over-
expressing breast cancers that have progressed on trast-
uzumab. Triciribine, a synthetic tricyclic nucleoside that
selectively inhibits phosphorylation of all Akt isoforms
but does not inhibit upstream Akt activators such as PI3K
[10], was shown to increase trastuzumab-mediated growth
inhibition and tumor regression in PTEN-deWcient trast-
uzumab-resistant breast cancer cells [11]. Another study
described PTEN-deWcient trastuzumab-resistant BT474 cell
lines, and showed in vitro re-sensitization and in vivo anti-
tumor eVects of combination Herceptin plus PI3K inhibitor
LY294002 [8]. However, despite these and other encourag-
ing preclinical results, LY294002 is not a clinically viable
agent, and thus could not be translated into practice.
In this study, we examined a clinically relevant small
molecule inhibitor of all isoforms of PI3K (pan-PI3K inhib-
itor) called SF1126 (Semafore Pharmaceuticals, Indianapo-
lis, IN) in HER2-over-expressing breast cancer cells and
trastuzumab-resistant derivatives of these cells created by
chronic, long-term exposure to trastuzumab [12,  13].
SF1126 is a chemically modiWed form of PI3K inhibitor
LY294002, with an RGDS peptide-linked integrin-targeted
(v3/51 targeted) group conjugated to the small mole-
cule PI3K inhibitor. This modiWcation is critical for
increasing the water solubility and half-life of LY294002,
hence facilitating clinical testing of this inhibitor [14].
SF1126 is currently in phase I trials for solid tumors including
recurrent breast cancer and multiple myeloma. We show
here that SF1126 inhibited proliferation and induced
apoptosis of trastuzumab-naïve and trastuzumab-resistant
HER2-over-expressing cells. In addition, the combination
of SF1126 and trastuzumab showed synergistic anti-prolif-
erative activity in trastuzumab-resistant cells. These results
suggest that SF1126 should be examined further as a poten-
tial therapeutic for HER2-over-expressing breast cancers,
including those that have become trastuzumab-resistant.
Materials and methods
Materials
Trastuzumab (Genentech; South San Francisco, CA) was
obtained from the Emory Winship Cancer Institute phar-
macy and dissolved in sterile water at a stock concentration
of 20 mg/ml. SF1126 was provided by Semafore Pharma-
ceuticals (Indianapolis, IN) to Dr. Donald L. Durden
(Emory University) at a stock concentration of 40 mM in
water, and was used in phenol red-free cell culture media as
previously described [14].
Cell culture
SKBR3 and BT474 parental cells were purchased from
ATCC (Manassas, VA). Trastuzumab-resistant cells
derived from SKBR3 and BT474 were developed as
previously described [12, 13]. BrieXy, SKBR3 or BT474
cells were maintained in 4 g/ml trastuzumab for
3 months, at which point the resistant pools were devel-
oped by collecting all viable cells on one plate; clones
were developed by propagating a single colony of viable
cells on a plate. Resistance to trastuzumab was conWrmed
by trypan blue exclusion or MTS proliferation assays and
previously published [12, 13]. Resistant cells are main-
tained on 4 g/ml trastuzumab. All cells are maintained in
Dulbecco’s modiWed Eagle’s medium supplemented with
10% fetal calf serum (FCS) and 1% penicillin/streptomy-
cin, and incubated at 37ºC with 5% CO2 in humidiWed
incubator.
Dose-response assays
Cells were plated at 5,000 per well in 96-well format, and
treated with twofold serial dilutions of SF1126 for 6 days,
at which point the cell proliferation was measured using the
colorimetric MTS assay (Promega; Madison, WI). Experi-
ments were done in six replicates and performed at least
twice. Proliferation is expressed as a percentage of
untreated cells per individual line; error bars represent stan-
dard deviation between replicates.Cancer Chemother Pharmacol (2010) 65:697–706 699
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Immunoblotting
Cells were lysed in RIPA buVer (Cell Signaling; Danvers,
MA), which includes 0.1% NP40, supplemented with pro-
tease and phosphatase inhibitor cocktails (Sigma; St. Louis,
MO). Total protein extracts (50 g) were run on SDS-
PAGE and immunoblotted using the following antibodies
at the indicated dilutions: from Cell Signaling, p-Thr308-
Akt (polyclonal C31E5E) (1:500), p-Ser473-Akt (monoclo-
nal 587F11) (1:200), polyclonal antibodies against total
Akt, p-Thr202/Tyr204 p42/p44 MAPK (ERK1/2), total
p42/p44 MAPK (ERK1/2), each used at 1:1,000, caspase 3
polyclonal (1:200), and PARP polyclonal used at 1:200;
from Santa Cruz Biotechnology (Santa Cruz, CA), survivin
monoclonal D-8 used at 1:500; and from Sigma, -actin
monoclonal used at 1:20,000. Secondary antibodies were
chosen according to the species of origin of the primary
antibody. Protein bands were detected using the Odyssey
Imaging System (Li-Cor Biosciences).
Cell cycle analysis
Cells were untreated or treated with 40-M SF1126 in
duplicate for 48 h, Wxed overnight in 50% ethanol, and then
resuspended in PBS containing propidium iodide (50 g/
mL) supplemented with RNase A (1 g/mL). DNA content
was measured using a FACScan Xow cytometer (Becton
Dickinson, Franklin Lakes, NJ).
Colony inhibition assays
Cells were plated at 100,000 cells per 6-well. After 24 h,
cells were untreated or treated with 20-M SF1126 for
48 h. Drug-containing media were then removed, cells were
washed with PBS, and drug-free media were added to cul-
tures. Cells were maintained for an additional 6 days, at
which point colonies were stained with 1% methylene blue.
Imaging was performed using the Odyssey System (Li-Cor
Biosciences; Lincoln, NE). Experiments were performed in
duplicate at least twice.
Drug combination analysis
SK-HRp2 and BT-HRp3 cells were plated at 5,000 per well
in 96-well format, and treated with SF1126 at 3.25, 7.5, 15,
or 30 M; trastuzumab at 1, 2, 4, or 8 g/mL; or a combina-
tion of SF1126 + trastuzumab at 3.25 M+1g/mL,
7.5 M+2g/mL, 15 M+4g/mL, or 30 M+8g/
mL. After 6 days, MTS reagent was added per manufac-
turer (Promega) instructions. All samples were done in six
replicates. Cell proliferation is expressed as a percentage of
untreated cells per individual line; error bars represent stan-
dard deviation between replicates. Statistical analysis of
drug combination eVects and combination index (CI) was
obtained using the method of Chou and Talalay [15] in the
commercial software package Calcusyn (Biosoft, Cambridge,
United Kingdom). CI > 1 indicates antagonism between
drugs, CI = 1 indicates additive eVects, CI < 1 indicates
drug synergy.
Soft agar assays
Anchorage-independent growth was assayed by colony for-
mation on soft agar. BrieXy, equal volumes of agar (1.2%)
and phenol red-free complete medium were mixed to make
0.6% agar growth medium solution in 6-well tissue culture
plates. Cells (50,000 cells/well) were suspended in phenol
red-free media with or without treatment followed by mix-
ing with equal volume of agar (0.6%). Cell suspension-agar
mix (2 mL) was then added to each well. Plates were incu-
bated at 37ºC with 5% CO2 in humidiWed incubator for
2 weeks, and media with or without treatment were added
every 3 days. Colonies were stained with 0.01% crystal vio-
let in PBS for 45 min at room temperature and observed
using Olympus IX50 inverted microscope with 5£ objec-
tive. Colonies that are equal to or bigger than average size
from four randomly selected non-overlapping Welds were
counted.
Results
SF1126 inhibits proliferation of HER2-over-expressing 
breast cancer cells
SKBR3 trastuzumab-resistant pool 2 (SK-HRp2) and clone
3 (SK-HRc3) cells were developed by long-term treatment
of HER2-over-expressing SKBR3 (SK-parental) breast
cancer cells with trastuzumab, as previously described [12].
SK-parental, SK-HRp2, and SK-HRc3 were treated with
increasing concentrations of SF1126 ranging from 7.5 to
120 M for 6 days. Proliferation was determined by MTS
assay, and is expressed as a percentage of untreated cells
per cell line (Fig. 1a). Proliferation was inhibited by
SF1126 in a dose-dependent manner, with SK-parental and
SK-resistant cells demonstrating similar responses with
IC50 values of approximately 30–60 M.
In addition to SKBR3-derived resistant cells, we gener-
ated BT474 trastuzumab-resistant pool 2 (BT-HRp2) and
pool 3 (BT-HRp3) cells using the same approach as used to
generate the trastuzumab-resistant SKBR3 cells [13]. BT-
parental, BT-HRp2, and BT-HRp3 cells were treated with
SF1126 ranging from 7.5 to 120 M for 6 days. Cell prolif-
eration was determined by MTS assay, and is expressed as
a percentage of untreated cells per line (Fig. 1b). Similar to
SKBR3 parental and resistant cells, BT474 cells displayed700 Cancer Chemother Pharmacol (2010) 65:697–706
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dose-dependent inhibition of proliferation. BT-parental and
BT-HRp3 showed IC50 values of approximately 30 M,
while BT-HRp2 appeared to be slightly more sensitive with
an IC50 of approximately 15 M-SF1126.
SF1126 promotes G1 arrest and induces apoptosis 
of HER2-over-expressing cells
Cells were either untreated or treated with 40-M SF1126.
After 48 h, cells were Wxed and stained with propidium
iodide, and analysis of DNA content was performed by
Xow cytometry. Representative cell cycle proWles are
shown for SK-parental and SK-HRp2 cells (Fig. 2a), and
for BT-parental and BT-HRp3 cells (Fig. 2b). The percent-
age of SF1126-treated SK-parental and SK-HRp2
(Fig. 2c) and BT-parental and BT-HRp3 (Fig. 2d) cells in
the proliferating fraction was reduced, and the percentage
in G1 was increased, indicating G1 arrest. For all cell lines,
SF1126 treatment resulted in an increase in the percentage
of cells with sub-diploid DNA content (Fig. 3a). Parental
cells showed approximately twofold increase in sub-diploid
cells, while trastuzumab-resistant cells showed an eightfold
increase in the percentage of sub-diploid cells, suggesting
induction of apoptosis by SF1126.
SK-parental, SK-HRp2, BT-parental, and BT-HRp2
were treated with 0 or 20-M SF1126 for 48 h. Cells were
then maintained in drug-free media for an additional week,
at which point colonies were stained with methylene blue
(Fig. 3b). SF1126 treatment resulted in inhibition of colony
growth, consistent with inhibition of proliferation and
induction of cell death in both parental and resistant
SKBR3 and BT474 cells.
To conWrm that SF1126-mediated cell death was due to
induction of apoptosis, SK-parental and SK-HRp2 cells
(Fig. 3c) and BT-parental and BT-HRp2 cells (Fig. 3d)
were treated with 0, 10, 20, or 40-M SF1126 for 24 h.
Cleavage of poly (ADP-ribose) polymerase (PARP) and
caspase 3, and expression of the anti-apoptotic molecule
survivin were measured by immunoblotting. During apop-
tosis, caspase 3 is cleaved into 17 and 19-kDa proteins, and
PARP is cleaved by caspases to produce an 89-kDa frag-
ment from the full-length 116-kDa protein. SF1126 induced
cleavage of PARP and caspase 3 in SKBR3 and BT474
parental and resistant cells consistent with induction of
apoptosis. Consistent with the MTS proliferation assays,
BT-parental and BT-HRp2 appeared slightly more sensitive
than the SKBR3 parental and resistant cells, as cleavage of
PARP and caspase 3 was more signiWcant in the BT474
cells, especially when treated with the highest 40-M dose
of SF1126. In addition, the anti-apoptotic molecule survi-
vin was down-regulated in parental and resistant cells
treated with SF1126. Together, these results indicate that
SF1126 blocks proliferation with induction of G1 arrest and
apoptosis in HER2-over-expressing breast cancer cells
including those that are resistant to trastuzumab.
SF1126 inhibits PI3K but not MAPK 
in trastuzumab-resistant cells
To assess the ability of SF1126 to inhibit its intended target
(PI3K) in HER2-over-expressing breast cancer cells,
immunoblotting was performed to detect phosphorylation
of the PI3K substrate Akt. SK-parental, SK-HRp2, BT-
parental, and BT-HRp2 were treated with 10, 20, or 40-M
SF1126 for 30 min. Phosphorylation of Akt on serine 473
(S473) and threonine 308 (T308) is regulated by PI3K,
3-phosphoinositide-dependent protein kinase-1 (PDK-1), and
mTOR. Thus, we assessed p-T308Akt and p-S473Akt as
indicators of PI3K activity. Phosphorylation of S473Akt
Fig. 1 SF1126 inhibits proliferation of parental and trastuzumab-
resistant HER2-over-expressing breast cancer cells. a Parental
SKBR3 HER2-overexpressing breast cancer cells (SK-parental),
SKBR3-derived trastuzumab-resistant pool 2 (SK-HRp2) and clone 3
(SK-HRc3), and b parental BT474 HER2-overexpressing breast can-
cer cells (BT-parental), BT474-derived trastuzumab-resistant pool 2
(BT-HRp2) and pool 3 (BT-HRp3) were treated with twofold serial
dilutions of SF1126 ranging from 7.5 to 120 M for 6 days. Cell pro-
liferation was measured using the MTS colorimetric assay, and is ex-
pressed as a percentage of untreated cells per line. Error bars represent
standard deviation between six replicates. SF1126 inhibited the prolif-
eration of parental and trastuzumab-resistant SKBR3 and BT474
HER2-overexpressing breast cancer cells
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was reduced with 40-M SF1126 in SKBR3 (Fig. 4a) and
10–20 M SF1126 in BT474 cells (Fig. 4c). Phosphoryla-
tion of T308 was inhibited with 10–20 M SF1126 in
SKBR3 (Fig. 4b) and BT474 (Fig. 4d) cells. In contrast,
ERK1/2 phosphorylation was not signiWcantly aVected,
demonstrating relative speciWcity of SF1126 for Akt regu-
lators including PI3 kinase, and possible inhibitory eVects
on PDK-1 and mTOR. BT474 cells appeared to be more
sensitive to PI3K inhibition with reduced p-T308Akt
and p-S473Akt levels achieved with 10-M SF1126. These
results are consistent with proliferation assays, which
showed stronger inhibition of proliferation by SF1126 in
BT474 cells versus SKBR3 cells, with BT-HRp2 being
more sensitive in that assay, and indicate that SF1126
inhibits its intended target (PI3-kinase) in HER2-over-
expressing breast cancer cells.
Combination SF1126 and trastuzumab synergistically 
block proliferation of trastuzumab-resistant cells
SK-HRp2 (Fig. 5a) and BT-HRp3 (Fig. 5b) were treated
with SF1126 at 3.25, 7.5, 15, or 30 M, trastuzumab at 1, 2,
4, or 8 g/mL, or a combination of the two drugs. Pharma-
cokinetic studies in vivo have conWrmed that the concentra-
tions of SF1126 used in these experiments are achieved in
vivo in xenografted tumor tissues [14]. Proliferation was
assessed by MTS assay after 6 days of treatment. Trast-
uzumab showed minimal to no inhibition of proliferation in
resistant cells. SF1126 alone showed an IC50 of approxi-
mately 30 M in SK-HRp2 and 15 M in BT-HRp3. The
combination of SF1126 and trastuzumab achieved an IC50
of less than 15 M in SK-HRp2 and approximately
3.25 M in BT-HRp3, suggesting that SF1126 increases
trastuzumab activity in resistant cells. Statistical analysis of
the combination dose-eVect (Table 1) demonstrated CI val-
ues less than 1.0 in both SK-HRp2 and BT-HRp3, indicat-
ing drug synergy. The synergy was stronger in BT-HRp3,
with CI values at low dose combinations ranging from 0.1
to 0.3, versus SK-HRp2, which had CI values of approxi-
mately 0.7. The CI values at ED90 were likely higher
because SF1126 had such high activity as a single agent,
and reaching the eVective dose at which 90% cells were
killed (ED90) was likely already achieved by the higher
doses of SF1126 used in these experiments. Overall, these
Fig. 2 SF1126 induces G1 arrest and inhibits proliferation. Cells were
either untreated or treated with 40-M SF1126 for 48 h, at which point
they were Wxed and stained with propidium iodide. DNA content was
then analyzed by Xow cytometry. Representative cell cycle proWles are
shown for a SK-parental and SK-HRp2, and b BT-parental and
BT-HRp3 cells. The percentages of c SK-parental and SK-HRp2cells,
and  d BT-parental and BT-HRp3 cells in G0/G1, S, or G2/M are
shown. SF1126 induced cell cycle arrest at the G1 phase with reduced
S phase (proliferating fraction) in all cells
Untreated            SF1126
SK-parental
SK-HRp2
Untreated            SF1126
BT-parental
BT-HRp3
SK-parental
Untreated      SF1126
SK-HRp2
Untreated      SF1126
G2/M
S
G0/G1
G2/M
S
G0/G1 41.2
56.1
22.6
11.5
33.5 25.8
37.4
55.1
24.6
15.5
37.4
21.0
32.2
55.2
50.4
10.7
11.5
25.4
BT-parental
Untreated      SF1126
43.1
61.0
23.2
7.9
32.8 22.5
BT-HRp3
Untreated      SF1126
G0/G1
S
G2/M G2/M
S
G0/G1
AB
D C702 Cancer Chemother Pharmacol (2010) 65:697–706
123
results demonstrate that the combination treatment of trast-
uzumab plus SF1126 synergistically blocks proliferation of
trastuzumab-resistant cells, and suggest that when used in
combination, each drug may be administered at a lower
dose versus when given as single agents.
In addition to proliferation assays, we examined the
eVect of combination treatment on anchorage-independent
growth. Resistant cells were plated in soft agar with 15-M
SF1126, 4 g/mL trastuzumab, or a combination of both
drugs for 2 weeks, at which point colonies were stained and
counted in four random non-overlapping Welds under a
microscope. Trastuzumab showed minimal inhibition of
colony growth, while SF1126 alone caused 50–90% growth
inhibition (Fig. 5c). Combined trastuzumab plus SF1126
achieved slightly stronger inhibition of colony growth than
SF1126 alone in all resistant cells. Thus, SF1126 appears to
increase trastuzumab-mediated growth inhibition in HER2-
over-expressing breast cancer cells that have become resis-
tant to trastuzumab.
Discussion
In the current study, we examined the PI3K inhibitor
SF1126 for activity against in vitro models of HER2-over-
expressing breast cancer, including those that have devel-
oped trastuzumab resistance. SF1126 inhibited proliferation
and colony formation, induced G1 arrest, and promoted
apoptosis of HER2-overexpressing breast cancer cells, with
relatively equal sensitivity between trastuzumab-naive and
trastuzumab-resistant cells per line. SF1126 appeared to be
speciWc for its intended target (PI3K), as Akt phosphoryla-
tion was reduced, while ERK1/2 phosphorylation was
largely unaVected. Importantly, the combination of SF1126
and trastuzumab synergistically inhibited proliferation of
trastuzumab-resistant cells, with combination indices less
than 1.0. Anchorage-independent growth assays showed
that SF1126 alone has strong inhibitory activity against
trastuzumab-resistant cells, with addition of trastuzumab
further increasing this inhibitory activity. Hence, SF1126
Fig. 3 SF1126 induces apoptosis of parental and trastuzumab-resis-
tant cells. a SK-parental, SK-HRp2, BT-parental, and BT-HRp3 cells
were either untreated or treated with 40-M SF1126 for 48 h, at which
point they were Wxed and stained with propidium iodide. DNA content
was analyzed by Xow cytometry. The percentages of cells with sub-
diploid DNA content are shown, with error bars representing standard
deviation between duplicates. SF1126 increased the percentage of
cells in sub-G1, consistent with induction of apoptosis. b Cells were
untreated or treated with 20-M SF1126 for 48 h, at which point the
drug-containing media were removed and replaced with drug-free
media. Cells were maintained for an additional 6 days, then stained
with methylene blue and photographed with the Odyssey Imaging
System. Experiments were done in duplicate at least two times.
Representative cultures are shown for each group. SF1126 inhibited
colony survival. c SK-parental and SK-HRp2cells, and d BT-parental
and BT-HRp2 cells were treated with 0, 10, 20, or 40-M SF1126 for
24 h. Total protein lysates (50 g) were immunoblotted for PARP,
cleaved caspase 3, and survivin. Actin served as a loading control.
SF1126 induced cleavage of PARP and caspase 3, and caused down-
regulation of survivin. These results indicate that SF1126 promotes
growth arrest and apoptosis of HER2-over-expressing breast cancer
cells
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appears to be an eVective anti-cancer agent in HER2-over-
expressing breast cancer cells, with activity retained in
trastuzumab-resistant cells.
SF1126 is a chemically modiWed form of the commer-
cially available PI3K inhibitor LY294002, with an RGDS
peptide-linked integrin-targeted (v3/51 targeted)
group conjugated to the small molecule PI3K inhibitor. The
integrins v3 and 51 are known to be expressed on the
surface of neoplastic cells including SKBR3 cells [16],
which are used in this study. As the increased eYcacy of
SF1126 versus LY294002 is believed to be due to the inte-
grin-targeting RGDS peptide, cells that express these inte-
grins should show increased response to SF1126 versus
LY294002. If cells did not express the integrins, one may
predict that cells will respond to SF1126 in a similar man-
ner as to LY294002. Thus, we expect that the expression of
integrins v3/51 on the cell surface increases response
to SF1126. In addition, integrins are expressed on neovas-
culature [17], facilitating targeting of SF1126 to endothelial
cells and allowing inhibition of angiogenesis [14]. Inhibi-
tion of angiogenesis, in addition to PI3K inhibition, may be
an important mechanism of anti-tumor activity of SF1126
to be studied in animal models and clinical trials. Thus, the
in vivo eVects of SF1126 against trastuzumab-resistant
breast cancer may be more pronounced than what we have
observed in vitro.
SF1126 was the Wrst pan-PI-3 kinase inhibitor to enter
human clinical trials. It was shown in preclinical models to
have single agent activity against breast cancer xenografts
[14]. This agent is currently in phase I clinical trials in
patients with breast, prostate, endometrial, and GIST
tumors. Future studies will examine SF1126 and additional
clinically relevant PI3K inhibitors using in vivo xenograft
models of HER2-over-expressing trastuzumab-resistant
breast cancer. These future studies will be necessary to
establish strong rationale for clinical development of
SF1126 and other PI3K inhibitors in the trastuzumab-resis-
tant setting. In vivo studies will also allow us to determine
dose-limiting toxicities of PI3K inhibition by SF1126 and
doses required to achieve tumor response. Although doses
of SF1126 required for in vitro activity were in the M
range, combination with trastuzumab allowed SF1126
doses to be reduced due to synergy between the two agents.
Additionally, combination with chemotherapy would be
expected to further decrease the dose of SF1126 required
for in vivo eVects. These studies are pending and will give
critical information for future development of this novel
PI3K inhibitor.
PI3K inhibition is an important molecular mechanism of
the anti-cancer action of trastuzumab, as hyper-activation
of PI3K signaling is associated with resistance to trast-
uzumab [8,  9]. The speciWc molecular change inducing
PI3K activity may vary among trastuzumab-resistant can-
cers, but has been reported to include PTEN loss [8], PI3K
p110 subunit mutation [9], and increased activation of
upstream growth factor receptors such as EGFR and IGF-IR
[18–20]. Our results support the concept that PI3K inhibition
is an important treatment approach for HER2-over-expressing
breast cancers that have become resistant to trast-
uzumab. Previously published pre-clinical results showed
Fig. 4 SF1126 inhibits PI3K signaling. a,  b SK-parental and SK-
HRp2, and c, d BT-parental, BT-HRp2 or BT-HRc3 cells were treated
with 0, 10, 20, or 40-M SF1126 for 30 min. Total protein lysates
(50 g) were immunoblotted for a, c phosphorylated serine 473
(p-S473) Akt, total Akt, phosphorylated Thr202/Tyr204 ERK1/2, and
total ERK1/2, and for b, d phosphorylated threonine 308 (p-T308) Akt
and total Akt. Actin served as a loading control. Parental and resistant
SKBR3 cells showed reduced p-S473Akt with 40-M SF1126 and
reduced p-T308Akt with lower doses of 10–20 M SF1126. BT-paren-
tal and resistant cells showed reduced p-S473Akt and p-T308Akt at
10–20 M SF1126. ERK1/2 phosphorylation was not signiWcantly
altered by SF1126
Total Akt
p-S473 Akt
p-ERK1/2
Total ERK1/2
0     10     20     40
SK-Parental SK-HRp2
0     10     20     40
0     10     20     40
SK-Parental SK-HRp2
0     10     20     40
Total Akt
p-T308 Akt
0     10     20     40
BT-Parental BT-HRp2
0      10     20     40
Total Akt
p-ERK1/2
Total ERK1/2
p-S473 Akt
0     10     20     40
BT-Parental BT-HRc3
0      10     20     40
Total Akt
p-T308 Akt
AB
CD704 Cancer Chemother Pharmacol (2010) 65:697–706
123
that combining trastuzumab with either the Akt inhibitor
triciribine or the mTOR inhibitor Rad001 caused regression
of trastuzumab-resistant tumors to a greater degree than either
agent alone [11]. Our results showed that SF1126 and
trastuzumab synergistically inhibit proliferation of trast-
uzumab-resistant cells. The implication of each of these
Wndings is that trastuzumab resistance may not be due to
permanent molecular changes, as PI3K inhibition restored
trastuzumab activity at least to some degree. This is supported
by results from a recent phase 1 clinical trial in which
RAD001 appeared to reverse trastuzumab resistance in
patients with metastatic HER2-positive cancers [21].
In addition to PI3K inhibition, several other combination
treatment strategies have been proposed for trastuzumab-
resistant breast cancers. Lapatinib, a dual EGFR/HER2
kinase inhibitor, has been shown to be eVective in pre-clini-
cal models of trastuzumab resistance [22, 23]. The combi-
nation of lapatinib and trastuzumab has been demonstrated
to have encouraging clinical activity in heavily pre-treated
trastuzumab-resistant metastatic breast cancers [24]. Dual
targeting of IGF-IR and HER2 is also a strategy of interest
based on in vitro data suggesting possible up-regulation of
IGF-IR expression or activation in trastuzumab resistance
[19, 20]. We previously reported that the combination of
HER2 antibodies trastuzumab and 2C4 (pertuzumab) syn-
ergistically induce cell death of HER2-over-expressing
BT474 breast cancer cells [25], and these promising results
were recently conWrmed in a phase 2 clinical trial [26]. As
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Fig. 5 Combination SF1126 and trastuzumab synergistically inhibit
proliferation of trastuzumab-resistant cells. a SK-HRp2 and b BT-
HRp3 cells were treated with 0, 3.25, 7.5, 15, or 30-M SF1126 (SF);
0, 1, 2, 4, or 8 g/mL trastuzumab (HCT); or combination SF + HCT.
After 6 days, MTS colorimetric assays were performed to measure cell
proliferation. Values are expressed as a percentage of untreated cells
per line. Error bars represent standard deviation between six repli-
cates. The combination of trastuzumab with SF1126 inhibited prolifer-
ation of SK-HRp2 and BT-HRp3 more than SF1126 alone. (Results of
statistical analysis are shown in Table 1.) c SK-HRp2, SK-HRc3, BT-
HRp2, and BT-HRp3 were plated in soft agar assays and untreated (U)
or treated with trastuzumab (H) at 4 g/mL, SF1126 (S) at 15 M, or
the combination of drugs (H + S) at these doses. After 2 weeks of
maintaining cells on drugs, colonies were stained with crystal violet
and counted under a microscope in four random non-overlapping
Welds. The average number of colonies was calculated and is shown as
a percentage of the average number of colonies in the untreated group
per line. Error bars represent standard deviation of colony numbers be-
tween selected Welds. SF1126 alone reduced colony growth by 50–
90%, and combination with trastuzumab achieved stronger growth
inhibition than SF1126 alone
Table 1 Combination index (CI) values for SF1126 plus trastuzumab
in resistant cells
SK-HRp2 and BT-HRp3 cells were treated with 0, 3.25, 7.5, 15, or
30-M SF1126 (SF); 0, 1, 2, 4, or 8 g/mL trastuzumab (HCT); or
combination SF + HCT. After 6 days, MTS colorimetric assays were
performed to measure cell proliferation. Statistical analysis of drug
combination eVects and CI was obtained using the method of Chou and
Talalay [15] in the commercial software package Calcusyn (Biosoft,
Cambridge, UK)
CI > 1 indicates antagonism between drugs, CI = 1 indicates additive
eVects, CI < 1 indicates drug synergy, ED50 eVective dose at which
50% cells are killed, ED75 eVective dose at which 75% cells are killed,
ED90 eVective dose at which 90% cells are killed
Cell name ED50 ED75 ED90
SK-HRp2 0.61644 0.66352 0.73506
BT-HRp3 0.28349 0.10304 4.52276
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stated above, the combination of mTOR inhibition by
RAD001 with paclitaxel and trastuzumab resulted in
impressive activity in patients with heavily pre-treated
trastuzumab-resistant metastatic breast cancer [21]. Finally,
proteasome inhibition is a possible approach for restoring
trastuzumab sensitivity based on pre-clinical results show-
ing synergy between trastuzumab and the proteasome
inhibitor bortezomib in HER2-overexpressing cells [27].
In conclusion, combining trastuzumab with additional
targeted inhibitors may be an eVective treatment strategy
for trastuzumab-resistant breast cancers. Since PI3K is a
central intercept node for a large number of signaling path-
ways in mammalian cells [17], many of which may be
hyper-activated in trastuzumab resistance, combined HER2
and PI3K inhibition is an attractive therapeutic approach.
Multiple clinically relevant PI3K or mTOR inhibitors are
currently being developed and tested in combination with
trastuzumab. Our study is the Wrst to demonstrate that a
pan-PI-3 kinase inhibitor that is in clinical development is
eVective in trastuzumab-resistant cells, and supports further
analysis of PI3K inhibitor SF1126 as a single agent or in
combination with trastuzumab in HER2-over-expressing
breast cancers, including those that have progressed on
trastuzumab-based therapy.
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